37964-14-0

Usage

Synthesis Reference(s)

Tetrahedron, 28, p. 667, 1972 DOI: 10.1016/0040-4020(72)84030-4

Upstream product

• 16205-98-4 3-oxo-cyclohexanecarboxylic acid 
• 100-63-0 phenylhydrazine 
• 636-94-2 2-hydroxyterephthalic acid 

Relevant academic research and scientific papers

TRICYCLIC CYTOPROTECTIVE COMPOUNDS

Compounds of formula (I): in which: X is a group of formula >CR1R2 or >SO2; Y is a group of formula >NH or >CR1R2; Z is a group of formula >C=O or >CH2 or a direct bond; R1 hydrogen and R2 is hydrogen, carboxy or hydroxy; or R1 and R2 together represent an oxo group, a methylenedioxy group or a hydroxyimino group; R3 is hydrogen or lower alkyl; R4 represents two hydrogen atoms, or an oxo or hydroxyimino group; R5 is hydrogen, lower alkyl or halogen; R6 is hydrogen, lower alkoxy or carboxy; R7 and R8 are each hydrogen, lower alkyl or halogen; and pharmaceutically acceptable salts and esters thereof can be used for the treatment or prophylaxis of acute or chronic neurodegenerative diseases or conditions such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Chorea, Multiple Sclerosis or the sequelae to acute ischaemic events such as heart attack, stroke or head injury and for protection against ischaemic damage to tissues of peripheral organs.

Fused indolecarboxamides: dopamine receptor subtype specific ligands

Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof wherein: R1and R2are the same or different and represent hydrogen, C1-C6alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-C6alkoxy, —O2CR′, —NHCOR′, —COR′, —SOmR′, where R′ is C1-C6alkyl and wherein m is 0, 1 or2; or R1and R2independently represent —CONR′R″, or —NR′R″ where R′ and R″ independently represent hydrogen or C1-C6alkyl; R3is hydrogen, C1-C6alkyl, or —COR′″ where R′″ is C1-C6alkyl; R4is hydrogen or C1-C6alkyl; and R represents an azacycloalkylalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dysronia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention are useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

Fused indolecarboxamides: dopamine receptor subtype specific ligands

Disclosed are compounds of the formula: STR1 or the pharmaceutically acceptable acid addition salts thereof wherein: STR2 represents an aromatic or alicyclic ring; R 1 and R 2 are the same or different and represent hydrogen, C 1 -C 6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C 1 -C 6 alkoxy, --O 2 CR'', --NHCOR'', --COR'', --SO m R'', where R'' is C 1 -C 6 alkyl and wherein m is 0, 1 or 2; orR 1 and R 2 independently represent --CONR''R"", or --NR''R"" where R'' and R"" independently represent hydrogen or C 1 -C 6 alkyl;R 3 is hydrogen, C 1 -C 6 alkyl, or --COR''"" where R''"" is C 1 -C 6 alkyl;R 4 is hydrogen or C 1 -C 6 alkyl; andR represents an aminoalkyl group,which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer''s disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention are useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

Cycloalkanoindoles. I. Synthesis and antiinflammatory actions of some acidic tetrahydrocarbazoles, cyclopentindoles, and cycloheptindoles

A novel series of acidic cycloalkanoindoles comprising tetrahydrocarbazole, cyclopentindole, and cycloheptindole 1 acetic acids has been synthesized via the Fischer indolization between a phenylhydrazine and a 1 alkyl 2 oxocycloalkaneacetic acid ester. Th